FDA-cleared profile

ClariCT.AI

ClariPI Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: ClariCT.AI assists radiologists and specialists by denoising and enhancing DICOM CT images of the head, chest, heart, and abdomen, including low-dose filtered-back-projection and iterative-reconstruction images, and transmitting processed images to a PACS workstation.

Clinical role
Post-processing analysis
Images and patients
CT/CTA · Head, chest, heart, and abdomen
Key limitation
Keep in mind: The indication is processing and enhancement of CT DICOM images; manufacturer neutrality is stated in the FDA indication.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: ClariCT.AI assists radiologists and specialists by denoising and enhancing DICOM CT images of the head, chest, heart, and abdomen, including low-dose filtered-back-projection and iterative-reconstruction images, and transmitting processed images to a PACS workstation.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head, chest, heart, and abdomen Input: DICOM CT images, including low-dose filtered-back-projection and iterative-reconstruction images from any CT scanner manufacturer/model within the labeled CT workflow.
  • Who uses it?Intended users: Radiologists and specialists.
  • What does the software produce?Output: Denoised and enhanced CT DICOM images transmitted to a PACS workstation.
  • What is its most important limitation?Key limitation: The indication is processing and enhancement of CT DICOM images; manufacturer neutrality is stated in the FDA indication.

Clinical takeaway. Clinical role: ClariCT.AI assists radiologists and specialists by denoising and enhancing DICOM CT images of the head, chest, heart, and abdomen, including low-dose filtered-back-projection and iterative-reconstruction images, and transmitting processed images to a PACS workstation.

Evidence takeaway. Evidence from the reviewed source record: The FDA summary describes nonclinical system, performance, phantom, and risk-based safety testing and states clinical studies were not required to demonstrate substantial equivalence.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
ClariCT.AI assists radiologists and specialists by denoising and enhancing DICOM CT images of the head, chest, heart, and abdomen, including low-dose filtered-back-projection and iterative-reconstruction images, and transmitting processed images to a PACS workstation.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Post-processing analysis
  • Exact FDA submission
  • Checked 2026-09-05
Required input
DICOM CT images, including low-dose filtered-back-projection and iterative-reconstruction images from any CT scanner manufacturer/model within the labeled CT workflow.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Denoised and enhanced CT DICOM images transmitted to a PACS workstation.
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Radiologists and specialists.
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
The indication is processing and enhancement of CT DICOM images; manufacturer neutrality is stated in the FDA indication.
  • Exact FDA submission
  • Checked 2026-09-05

No lesion-detection indication or uniform dose-reduction benefit is inferred. Predicate Zia restrictions in the comparison table are not copied as ClariCT.AI labeling.

Evidence summary
The FDA summary describes nonclinical system, performance, phantom, and risk-based safety testing and states clinical studies were not required to demonstrate substantial equivalence.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA summary describes nonclinical system, performance, phantom, and risk-based safety testing and states clinical studies were not required to demonstrate substantial equivalence.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No exact-submission lesion-detection sensitivity with population, endpoint, and threshold was established; denoising quality is not sensitivity.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No exact-submission lesion-detection specificity with population, endpoint, and threshold was established.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

ClariCT.AI K183460 nonclinical verification and validation

  • DesignNonclinical system, performance, phantom, and safety testing
  • PopulationPhantom and software inputs; clinical participant count not reported
  • Scopeexact submission
  • Tested versionClariCT.AI submitted in K183460; build not stated
  • IndependenceIndependence not established

K183460

Clinical studies were not required for substantial equivalence according to the summary.

Liver CT Dose Reduction With Deep Learning Based Reconstruction

  • DesignRegistered prospective multicenter observational cohort with noninferiority comparison
  • PopulationSuspected focal liver lesions; low-dose CT with ClariCT.AI compared with standard-dose CT using model-based iterative reconstruction.
  • Scopeproduct family
  • Tested versionClariCT.AI; exact release and K183460 equivalence not established
  • Samplen=300
  • Sites3
  • IndependenceIndependence not established

NCT05804799

Registry lists 300 actual enrollees, completed status, no posted results, and last update 2023-04-12. Sponsor: Seoul National University Hospital. Enrollment is not an analyzed-cohort count; sponsorship alone does not establish independence.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM CT images, including low-dose filtered-back-projection and iterative-reconstruction images from any CT scanner manufacturer/model within the labeled CT workflow.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · FDA 510(k) K183460: ClariCT.AI

  2. Routing

    Source context, not route validation: Receives DICOM CT images, performs denoising/enhancement, and transmits images to a PACS workstation.

    Scope: Exact FDA submission. Specific service classes and local PACS versions require conformance documentation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · FDA 510(k) K183460: ClariCT.AI

  3. AI processing

    Source context, not route validation: On-premise

    Scope: Product family. The baseline on-premises option is supported by current vendor desktop-PC installation information. Embedded and cloud options are also described at family scope; exact 2019 configuration linkage remains unresolved.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · ClariCT.AI official product and integration page

  4. Returned objects

    Source context, not route validation: Denoised and enhanced CT DICOM images transmitted to a PACS workstation.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · FDA 510(k) K183460: ClariCT.AI

  5. Viewer/worklist/report

    Unresolved route: Denoised and enhanced CT DICOM images transmitted to a PACS workstation.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · FDA 510(k) K183460: ClariCT.AI

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
On-premise
  • Product family
  • Checked 2026-09-05

The baseline on-premises option is supported by current vendor desktop-PC installation information. Embedded and cloud options are also described at family scope; exact 2019 configuration linkage remains unresolved.

Integration
Receives DICOM CT images, performs denoising/enhancement, and transmits images to a PACS workstation.
  • Exact FDA submission
  • Checked 2026-09-05

Specific service classes and local PACS versions require conformance documentation.

CT-to-PACS processing

Receives and denoises CT DICOM images and sends processed images to a PACS workstation.

exact submission · checked 2026-09-05

Current installation options

The vendor describes standalone desktop-PC use, embedding in CT/PACS systems, and cloud-based distribution/deployment.

product family · checked 2026-09-05

Not tied to the 2019 release or a current contract. Specific hardware, networking, and privacy requirements remain unverified.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K183460
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Head, chest, heart, and abdomen
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Explicit FDA device description broadens the baseline's cardiovascular-only normalization.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2019-06-13
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
27Fields reviewed
11Source classes checked
0Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads

Both stored trial metadata records screened. NCT05804799 live registry supports a contextual family study without exact-version results. NCT05577884 concerns ultra-low-dose whole-body CT in multiple myeloma; its direct page returned a shell and protocol/version linkage was not established, so no result was promoted. No stored PubMed candidates. The current discovery snapshot contains 0 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Care setting: Not verified - checked 2026-09-05 - Exact FDA submission

    CT-to-PACS use is described, but exhaustive patient-age and care-setting eligibility were not established in the reviewed text.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    The product page gives no scoped price. Software, workstation/GPU, installation, support, and upgrade costs need quotation; procurement research is incomplete.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "ClariCT.AI reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact FDA submission

    No dated, scoped attestation was reviewed. PHI handling, image-cache retention, access control, audit, and incident-response terms remain unverified.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    Current protocol/noise-setting training and support commitments were not established.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Dose/protocol-specific acceptance, original/processed image review, update control, and escalation require a site/vendor plan; these are editorial evaluation needs.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K183460: ClariCT.AI

    U.S. Food and Drug Administration - Published 2019-06-13 - Accessed 2026-09-05

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ClariCT.AI model card (K183460)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, integration, anatomy, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. ClariCT.AI official product and integration page

    ClariPi Inc. - Accessed 2026-09-05

    Scope: productFamilyWorkflow, deployment, implementationCapabilities

  8. NCT05804799: Liver CT Dose Reduction With Deep Learning Based Reconstruction

    ClinicalTrials.gov; record supplied by Seoul National University Hospital - Published 2023-04-12 - Accessed 2026-09-05

    Scope: contextualEvidenceStudy, studyStatus

Research history

  1. K183460 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253786

syngo.CT Coronary Cockpit

Siemens Medical Solutions USA, Inc.

Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2026-06-25
FDA-cleared K260324

Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

Canon Medical Informatics, Inc.

Authorized purpose: Assist assessment and pre-operative planning and post-operative evaluation of transcatheter aortic valve replacement procedures.

Modality
CT/CTA
Anatomy
Aortic valve/root, LVOT and ventricles, coronary ostia, cardiac structures, and iliac/femoral/abdominal aortic access vessels
Decision
2026-05-22
FDA-cleared K253596

Aquilion ONE (TSX-308A/TSX-306A) V2.0

Canon Medical Systems Corporation

Authorized purpose: Canon Aquilion ONE V2.0 acquires and processes whole-body CT volumes, including head, chest, abdomen, pelvis, cardiac, extremity, inner-ear, and multi-energy examinations with the labeled reconstruction functions.

Modality
CT/CTA
Anatomy
Whole body; head; chest; abdomen; pelvis; heart; extremities; and inner ear
Decision
2026-05-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history